Glyco-Immune Diagnostic Signatures and Therapeutic Targets of Mesothelioma
Abstract
This project is funded in order to investigate immunoprofiles of serum anti-glycan antibodies recognizing Mesothelioma-derived aberrant glycans in human subjects and in animal models of Mesothelioma. This is accomplished using a one of a kind printed glycan array which has been developed by us at the New York University School of Medicine (NYU SoM) and has now been expanded by addition of 177 novel glycan probes, many of which are Mesothelioma-specific. It is expected that the results of these experiments will allow us to diagnose and prognosticate Mesothelioma earlier during its development. 14. ABSTRACT We have established the new glyco-laboratory with the dedicated print-room which now allows printing of large batches of glycochips of an enhanced quality, and with an increased efficiency. We are now in a process of printing large batches of glycochips for AGA immunoprofiling in both human and our model-Meso-rat sera. We have re-grown and prepared for implantations pathogen-free rat syngeneic II-45 Mesothelioma cell line. The second arm of animal experiments involving implantations of rat Mesothelioma cells and treatments of the resulting tumors will begin as soon as our second study protocol is approved.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2012
- Accession Number
- ADA562005
Entities
People
- Harvey I Pass
Organizations
- New York University